Targeting Hypersumoylation in Mantle Cell Lymphoma
نویسندگان
چکیده
منابع مشابه
Targeting cyclin D1 for mantle cell lymphoma
Cyclin D1, an important component of cell cycle and a protein with known oncogenic potential, is over expressed in mantle cell lymphoma (MCL). MCL is a distinct clinical pathologic subtype of B cell non-Hodgkin’s lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are being developed. Targeting cyclin D1 for MCL is rendering an interes...
متن کاملTargeting Wnt pathway in mantle cell lymphoma-initiating cells
BACKGROUND Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-Hodgkin's lymphoma. Despite initial intense chemotherapy, up to 50% of cases of MCL relapse often in a chemoresistant form. We hypothesized that the recently identified MCL-initiating cells (MCL-ICs) are the main reason for relapse and chemoresistance of MCL. Cancer stem cell-related pathways such as Wnt could be r...
متن کاملTargeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.
The pentapeptide mimic 1,4-bis(9-O-dihydroquinidinyl)phthalazine / hydroquinidine 1,4-phathalazinediyl diether ("compound 61") (C-61) is the first reported inhibitor targeting the P-site of SYK. Here we report a nanotechnology platform to target C-61 to mantle cell lymphoma (MCL) cells. Liposomal nanoparticles (NP) loaded with C-61 were prepared using the standard thin film evaporation method. ...
متن کاملMantle Cell Lymphoma with Multiple Lymphomatous Polyposis Presenting With Intussusceptions
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. The gastrointestinal tract is the predominant site of extranodal involvement in the form of multiple lymphomatous polyposis. Multiple lymphomatous polyposis due to mantle cell lymphoma presenting with intussusception is ...
متن کاملMantle Cell Lymphoma
American Society of Hematology in the first 2 years has also been reduced by 50% in the rituximab-containing treatment arm. These preliminary findings in a pilot study echo the results of previously published studies in advanced disease and provide a lead for future comparative trials. Although the majority of patients with limited disease can be cured using a brief course of doxorubicincontain...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2019
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2019-127363